Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
11 juin 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
Cell Culture Market Is Expected To Reach A Revenue Of USD 80.3 Bn By 2033, At 11.0% CAGR: Dimension Market Research
10 juin 2024 10h53 HE
|
Dimension Market Research
New York, June 10, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Cell Culture Market size is expected to reach USD 31.4 billion by 2024 and is further anticipated to reach USD 80.3 billion...
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
10 juin 2024 08h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis Builds upon the positive...
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
10 juin 2024 07h00 HE
|
TransCode Therapeutics, Inc.
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
Macomics Announces Appointment of Simon Dew as New Chief Business Officer
10 juin 2024 04h00 HE
|
Macomics Limited
Macomics continues to expand its leadership team to accelerate the development of first-in-class macrophage-targeted therapiesSimon Dew brings over 25 years of experience in pharmaceutical business...
Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly
07 juin 2024 20h18 HE
|
Qu Biologics, Inc.
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial...
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
06 juin 2024 11h15 HE
|
Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
BioNTX Announces 10th Annual iC³® Life Science & Healthcare Innovation Summit
06 juin 2024 10h00 HE
|
Bio North Texas
BioNTX, the leading biotechnology trade organization in North Texas, is thrilled to announce the 10th Annual iC³® Life Science Summit.
Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer
06 juin 2024 08h00 HE
|
Qu Biologics, Inc.
BURNABY, British Columbia, June 06, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Global Metabolomics Report 2024: Market Poised for Substantial Growth, Expected to Reach $6.5 Billion by 2032, Fueled by Advancements in Personalized Medicine and Chronic Disease Prevalence
06 juin 2024 04h06 HE
|
Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Global Metabolomics Market Report by Product, Indication, Application, and Region 2024-2032" report has been added to ResearchAndMarkets.com's...